Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomic Sequencing Guided Therapy in Gastrointestinal Cancers
NCT02013089Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2013
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of erlotinib, gefitinib, everolimus, imatinib, sorafenib and 2 more in gastrointestinal cancer (6 arms), sponsored by Sun Yat-sen University. Primary endpoint: Overall Survival at 1 year. Status: unknown.
02
Drugs
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT02013089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013089.